Litcius/Paper detail

Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads

Danielle M. Lussier, Elise Alspach, Jeffrey P. Ward, Alexander P. Miceli, Daniele Runci, J. Michael White, Cedric Mpoy, Cora D. Arthur, Heather N. Kohlmiller, Tyler Jacks, Maxim N. Artyomov, Buck E. Rogers, Robert D. Schreiber

2021Proceedings of the National Academy of Sciences133 citationsDOIOpen Access PDF

Abstract

Significance Immune checkpoint therapy (ICT) has led to durable responses in a subset of cancer patients. Generally, patients who respond to ICT bear tumors with high mutational burden. Radiation is used for treatment of many types of cancers and has been shown to induce new mutations in treated tumor cells and to synergistically facilitate ICT. However, these latter actions have largely been explained by radiation-induced tumor cell death and/or effects on the host. Herein, we show that noncurative irradiation induces mutations in tumor cells lacking neoantigens and that these de novo-generated neoantigens function as targets for CD8 + T cells, resulting in increased immunogenicity of nonimmunogenic tumor cells. This study thus identifies an additional mechanism that explains synergy between immunotherapy and radiation.

Topics & Concepts

ImmunogenicityCancer researchCD8ImmunotherapyImmune systemRadiation therapyCancerMedicineCancer immunotherapyImmunologyBiologyInternal medicineCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads | Litcius